A year in the life of German patients with COPD: the DACCORD observational study

Figures & data

Table 1 Baseline demographics and disease characteristics

Demographics and characteristics	Overall population (N=3,974)	Excluded from per-protocol population (N=1,954)
Sex, n (%)
Male	2,362 (59.4)	1,176 (60.2)
Female	1,612 (40.6)	774 (39.8)
Age (years), mean (SD)	65.7 (10.1)	65.7 (10.6)
Age groups, n (%)
<65 years	1,809 (45.5)	903 (46.2)
65–75 years	1,492 (37.5)	670 (34.3)
>75 years	673 (16.9)	381 (19.5)
BMI (kg/m^2), mean (SD)	27.3 (5.6)	27.2 (5.6)
Duration since primary diagnosis, n (%)
≤1 year	963 (24.2)	619 (31.7)
>1 year	3,011 (75.8)	1,335 (68.3)
FEV1 (percent predicted),a n (%)
≥80	733 (18.4)	355 (18.2)
50 to <80	1,948 (49.0)	947 (48.5)
30 to <50	1,066 (26.8)	544 (27.8)
<30	227 (5.7)	108 (5.5)
Smoking status at baseline, n (%)
Ex-smoker	1,721 (43.3)	690 (35.3)
Current smoker	1,479 (37.2)	793 (40.6)
Never-smoker	738 (18.6)	400 (20.5)
Missing data	36 (0.9)	71 (3.6)
Symptoms at baseline, n (%)
Yes	3,860 (97.1)	1,838 (94.1)
No	111 (2.8)	91 (4.7)
Missing	3 (0.1)	25 (1.3)
mMRC dyspnea scale, mean (SD)	1.9 (1.0)	1.8 (1.1)
CAT score, mean (SD)	20.2 (7.6)	19.5 (7.9)

Note:

a Random spirometry assessed without requirement for washout of COPD medication or additional inhalation of short-acting β₂-agonist.

Abbreviations: SD, standard deviation; BMI, body mass index; FEV₁, forced expiratory volume in 1 second; mMRC, modified Medical Research Council; CAT, COPD Assessment Test.

Figure 1 Cohort 1 patient flow through the first year of DACCORD.

Abbreviation: DACCORD, Die ambulante Versorgung mit langwirksamen Bronchodilatatoren: COPD-Register in Deutschland [Outpatient Care With Long-Acting Bronchodilators: COPD Registry in Germany].

Figure 2 Annualized exacerbation rate (and 95% CI) during the 1-year follow-up period, in patients grouped according to baseline GOLD 2011 category.

Notes: Due to low patient numbers, rates were not calculated for the GOLD C subgroups. GOLD A, low symptoms, low risk; GOLD B, high symptoms, low risk; GOLD C, low symptoms, high risk; GOLD D, high symptoms, high risk; GOLD D1, high risk on the basis of lung function alone; GOLD D2, high risk on the basis of exacerbations alone; GOLD D3, high risk on the basis of exacerbations and lung function.
Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Table 2 Number (%) of patients reporting 0, 1, and ≥2 exacerbations over 1 yeara (per-protocol population; N=3,974)

Patients, n (%)	Number of exacerbations during the 1-year follow-up
	0	1	≥2
No exacerbations in the 6 months prior to baseline	1,876 (47.2)	386 (9.7)	140 (3.5)
At least one exacerbation in the 6 months prior to baseline	460 (11.6)	219 (5.5)	176 (4.4)

Note:

a The numbers reported in the table exclude patients with missing baseline data or with no exacerbation reported during the 1-year follow-up, and patients with an exacerbation reported, but the number of exacerbations not reported.

Figure 3 Percentage of patients reporting exacerbations at baseline and during the 1 year follow-up period (per-protocol population; N=3,974).

Figure 4 GOLD 2011 categorization at baseline and after 1 year (per-protocol population).

Notes: Six patients in category C and 21 in category D had insufficient data at the 1-year visit to be assigned to a subcategory and so are not included. GOLD A, low symptoms, low risk; GOLD B, high symptoms, low risk; GOLD C, low symptoms, high risk; GOLD D, high symptoms, high risk; GOLD C1/D1, high risk on the basis of lung function alone; GOLD C2/D2, high risk on the basis of exacerbations alone; GOLD C3/D3, high risk on the basis of exacerbations and lung function.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV₁, forced expiratory volume in 1 second.

Table 3 CAT total score (per-protocol population; N=3,974)

	Baseline CAT total score	CAT total score after 1 year
		Total score	Change from baseline
Mean (SD)	20.2 (7.6)	18.3 (7.8)	−1.9 (6.3)
1st quartile, 3rd quartile	15.0, 26.0	13.0, 24.0	−5.0, 1.0

Abbreviations: CAT, COPD Assessment Test; SD, standard deviation.

Figure 5 Percentages of patients persisting with, switching, or adding on medication classes at 1 year (per-protocol population).

Note: N=3,974 (data not evaluable for 78 patients).
Abbreviations: LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; PDE-4, phosphodiesterase-4.